| Name | Walgreens #15608 |
|---|---|
| Organization Name | Walgreen Co |
| Location | 520 Cedar Ln, Teaneck, New Jersey 07666 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (201) 347-3137 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories Limited of New Delhi, India, announced today that RLL has received approval from the U. S. Food and Drug Administration to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets
Isis Pharmaceuticals, Inc. announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company related to the acceptance of initial regulatory filings to begin Phase 1 clinical studies for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense drug that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to identify antisense drugs targeting PCSK9 to lower low-density lipoprotein (LDL) cholesterol.
Phone calls after Mohs micrographic skin surgery can address patient concerns and quickly identify complications.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
26.2 with DONNA The National Marathon to Finish Breast Cancer is thrilled to announce a stunning new development that could mean a vaccine for some women with Triple Negative Breast Cancer, an aggressive type of breast cancer that tends to strike young women, African American women, and women of Hispanic descent.
› Verified 4 days ago
| NPI Number | 1376093724 |
| Organization Name | WALGREEN CO |
| Doing Business As | WALGREENS #15608 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 520 Cedar Ln, Teaneck, NJ 07666 |
| Phone Number | 201-347-3137 |
News Archive
Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories Limited of New Delhi, India, announced today that RLL has received approval from the U. S. Food and Drug Administration to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets
Isis Pharmaceuticals, Inc. announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company related to the acceptance of initial regulatory filings to begin Phase 1 clinical studies for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense drug that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to identify antisense drugs targeting PCSK9 to lower low-density lipoprotein (LDL) cholesterol.
Phone calls after Mohs micrographic skin surgery can address patient concerns and quickly identify complications.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
26.2 with DONNA The National Marathon to Finish Breast Cancer is thrilled to announce a stunning new development that could mean a vaccine for some women with Triple Negative Breast Cancer, an aggressive type of breast cancer that tends to strike young women, African American women, and women of Hispanic descent.
› Verified 4 days ago
News Archive
Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories Limited of New Delhi, India, announced today that RLL has received approval from the U. S. Food and Drug Administration to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets
Isis Pharmaceuticals, Inc. announced today that it has earned a $6 million milestone payment from Bristol-Myers Squibb Company related to the acceptance of initial regulatory filings to begin Phase 1 clinical studies for BMS-PCSK9Rx. BMS-PCSK9Rx is an antisense drug that arose out of the ongoing collaboration between Bristol-Myers Squibb and Isis to identify antisense drugs targeting PCSK9 to lower low-density lipoprotein (LDL) cholesterol.
Phone calls after Mohs micrographic skin surgery can address patient concerns and quickly identify complications.
Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that since the 2008 retrospective analysis of patient-level claims data, Boehringer Ingelheim/Pfizer's Spiriva has closed the gap in patient share between itself and GlaxoSmithKline's Advair in newly diagnosed chronic obstructive pulmonary disease (COPD) patients. Although Advair's patient share in the first line is still greater than Spiriva's, Spiriva has surpassed Advair in the second line and will continue to overcome and widen the gap between itself and Advair over the next two years.
26.2 with DONNA The National Marathon to Finish Breast Cancer is thrilled to announce a stunning new development that could mean a vaccine for some women with Triple Negative Breast Cancer, an aggressive type of breast cancer that tends to strike young women, African American women, and women of Hispanic descent.
› Verified 4 days ago
Cvs Pharmacy # 02742 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 188 Cedar Ln, Teaneck, New Jersey 07666 Phone: (201) 287-4441 | |
Cvs Pharmacy #00289 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 540 Cedar Ln, Teaneck, New Jersey 07666 Phone: (201) 836-6990 | |
Cvs Pharmacy 03097 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 375 Queen Anne Rd, Teaneck, New Jersey 07666 Phone: (201) 928-2903 | |
Pedi-care Corp Type: Prosthetic/Orthotic Supplier Location: 1086 Teaneck Rd, Teaneck, New Jersey 07666 Phone: (201) 666-6647 |